PURPOSE: Oxidant stress may be an effect of antiretroviral therapy (ART) or chronic HIV infection. Plasma F2-isoprostanes (F2-IsoP) reflect lipid peroxidation and oxidant stress and have been described in ART-associated toxicities. We explored factors associated with F2-IsoP in HIV-infected adults. METHODS: HIV-infected adults enrolled in this cross-sectional study were (a) on ART including zidovudine or stavudine but not non-nucleoside reverse transcriptase inhibitors (NNRTI), (b) on ART including NNRTI, or (c) not on ART. Plasma F2-IsoP levels were quantified by GC/MS, and clinical and laboratory data were collected at enrollment. RESULTS: Among 285 participants, 24% were female, 37% were African American, and 194 (68%) were on ART; 44 (23%) of whom were receiving efavirenz, 45 (23%) nevirapine, and 85 (44%) protease inhibitors. Median F2-IsoP was lower in those on NNRTI than those on ART without NNRTI (p = .02). In a multivariable model, factors independently associated with increased F2-IsoP were female sex (p = .002), higher BMI (p = .01), and heavy smoking (p = .004). There was a trend toward lower F2-IsoP among nevirapine users (p = .054). CONCLUSIONS: Among HIV-infected adults, oxidant stress status differs by sex, BMI, smoking status, and perhaps specific ART. Prospective studies should better define relationships between oxidant stress and complications of HIV infection and its therapy.
PURPOSE: Oxidant stress may be an effect of antiretroviral therapy (ART) or chronic HIV infection. Plasma F2-isoprostanes (F2-IsoP) reflect lipid peroxidation and oxidant stress and have been described in ART-associated toxicities. We explored factors associated with F2-IsoP in HIV-infected adults. METHODS:HIV-infected adults enrolled in this cross-sectional study were (a) on ART including zidovudine or stavudine but not non-nucleoside reverse transcriptase inhibitors (NNRTI), (b) on ART including NNRTI, or (c) not on ART. Plasma F2-IsoP levels were quantified by GC/MS, and clinical and laboratory data were collected at enrollment. RESULTS: Among 285 participants, 24% were female, 37% were African American, and 194 (68%) were on ART; 44 (23%) of whom were receiving efavirenz, 45 (23%) nevirapine, and 85 (44%) protease inhibitors. Median F2-IsoP was lower in those on NNRTI than those on ART without NNRTI (p = .02). In a multivariable model, factors independently associated with increased F2-IsoP were female sex (p = .002), higher BMI (p = .01), and heavy smoking (p = .004). There was a trend toward lower F2-IsoP among nevirapine users (p = .054). CONCLUSIONS: Among HIV-infected adults, oxidant stress status differs by sex, BMI, smoking status, and perhaps specific ART. Prospective studies should better define relationships between oxidant stress and complications of HIV infection and its therapy.
Authors: J D Morrow; B Frei; A W Longmire; J M Gaziano; S M Lynch; Y Shyr; W E Strauss; J A Oates; L J Roberts Journal: N Engl J Med Date: 1995-05-04 Impact factor: 91.245
Authors: Myron Gross; Michael Steffes; David R Jacobs; Xinhua Yu; Linda Lewis; Cora E Lewis; Catherine M Loria Journal: Clin Chem Date: 2004-10-28 Impact factor: 8.327
Authors: Todd Hulgan; Jason Morrow; Richard T D'Aquila; Stephen Raffanti; Michael Morgan; Peter Rebeiro; David W Haas Journal: Clin Infect Dis Date: 2003-11-19 Impact factor: 9.079
Authors: Pablo Tebas; Kevin Yarasheski; Keith Henry; Sherri Claxton; E Kane; B Bordenave; Michael Klebert; William G Powderly Journal: AIDS Res Hum Retroviruses Date: 2004-06 Impact factor: 2.205
Authors: Ryszard Olinski; Daniel Gackowski; Marek Foksinski; Rafal Rozalski; Krzysztof Roszkowski; Pawel Jaruga Journal: Free Radic Biol Med Date: 2002-07-15 Impact factor: 7.376
Authors: T A Ikizler; J D Morrow; L J Roberts; J A Evanson; B Becker; R M Hakim; Y Shyr; J Himmelfarb Journal: Clin Nephrol Date: 2002-09 Impact factor: 0.975
Authors: J M Petit; M Duong; D Masson; M Buisson; L Duvillard; J B Bour; M C Brindisi; F Galland; M Guiguet; P Gambert; H Portier; B Vergès Journal: Eur J Clin Invest Date: 2004-08 Impact factor: 4.686
Authors: Kathleen S Montine; Joseph F Quinn; Jing Zhang; Joshua P Fessel; L Jackson Roberts; Jason D Morrow; Thomas J Montine Journal: Chem Phys Lipids Date: 2004-03 Impact factor: 3.329
Authors: Michael S Boger; Aihua Bian; Ayumi Shintani; Ginger L Milne; Jason D Morrow; Husamettin Erdem; Valerie Mitchell; David W Haas; Todd Hulgan Journal: Antivir Ther Date: 2011-12-14
Authors: Matthew B Crist; Vlada V Melekhin; Aihua Bian; Ayumi Shintani; Ginger L Milne; Asha R Kallianpur; Leigh A Dageforde; David W Haas; Todd Hulgan Journal: J Acquir Immune Defic Syndr Date: 2013-12-01 Impact factor: 3.731
Authors: Samir K Gupta; Changyu Shen; Sharon M Moe; Lisa M Kamendulis; Mitchell Goldman; Michael P Dubé Journal: PLoS One Date: 2012-09-20 Impact factor: 3.240
Authors: Todd Hulgan; M Sean Boger; Diana H Liao; Grace A McComsey; Christine A Wanke; Alexandra Mangili; Sharon L Walmsley; Heather McCreath; Ginger L Milne; Stephanie C Sanchez; Judith S Currier; Jordan E Lake Journal: Mediators Inflamm Date: 2014-06-01 Impact factor: 4.711